QUIDELORTHO CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
QUIDELORTHO CORP (QDEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $17.83 per share for the 12-month period ending 2025-12-28, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-19
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-04-02 was $47.83, a 7.65% decline year-over-year.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-04-03 was $51.79.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $17.83, a 26.84% decline from fiscal 2024.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $24.37, a 49.41% decline from fiscal 2023.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $48.17, a 4.84% decline from fiscal 2023.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $50.62, a 52.49% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2025-12-28 | $17.83 10-K · filed 2026-02-19 | ||||
| 2024-12-29 | $24.37 10-K · filed 2026-02-19 | ||||
| 2023-12-31 | $48.17 10-K · filed 2026-02-19 | ||||
| 2023-10-01 | $48.17 10-Q · filed 2023-11-02 | ||||
| 2023-07-02 | $48.17 10-Q · filed 2023-08-09 | ||||
| 2023-04-02 | $47.83 10-Q · filed 2023-05-04 | ||||
| 2023-01-01 | $50.62 10-K · filed 2025-02-27 | ||||
| 2022-10-02 | $50.86 10-Q · filed 2023-11-02 | ||||
| 2022-07-03 | $50.86 10-Q · filed 2023-08-09 | ||||
| 2022-05-27 | $40.57 10-K · filed 2023-02-23 | ||||
| 2022-04-03 | $51.79 10-Q · filed 2023-05-04 | ||||
| 2022-01-02 | $106.55 10-K/A · filed 2024-08-01 | ||||
| 2021-10-03 | $106.55 10-Q · filed 2022-11-04 | ||||
| 2021-07-04 | $115.78 10-Q · filed 2022-08-05 | ||||
| 2021-01-03 | $36.84 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |